NCT07148128View on ClinicalTrials.gov

Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

July 28, 2025

Primary Completion Date

January 31, 2028

Study Completion Date

January 31, 2028

Conditions
Advanced or Metastatic KRAS-mutant Tumor in Pancreatic AdenocarcinomaAdvanced or Metastatic KRAS-mutant Tumor in Colorectal CancerAdvanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung CancerAdvanced Solid TumorsAdvanced or Metastatic KRAS-mutant Tumor
Interventions
DRUG

WEF-001

Starting dose of 0.3 mg/m2 q4wks IV, dose escalation

Trial Locations (3)

75230

RECRUITING

NEXT Oncology Dallas, Dallas

78229

RECRUITING

Next Oncology, San Antonio, San Antonio

0X3 9DU

RECRUITING

Oxford University Hospital, Headington

Sponsors

Collaborators (1)

Simbec-Orion Group
All Listed Sponsors
collaborator

Simbec-Orion Group

INDUSTRY

lead

Auricula Biosciences Inc.

INDUSTRY

NCT07148128 - Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours. | Biotech Hunter | Biotech Hunter